Sodium-glucose transport proteins

Types

The sodium-glucose linked transporters (SGLTs) are responsible for the active transport of glucose across cell membranes. SGLT1 and SGLT2 are the most well-studied members of this family. Both SGLT1 and SGLT2 function as symporters, utilizing the energy from the sodium gradient created by the Na+/K+ ATPase to transport glucose against its concentration gradient.

SGLT2, encoded by the SLC5A2 gene, is predominantly expressed in the S1 and S2 segments of the proximal renal tubule and is responsible for approximately 97% of glucose reabsorption in the kidneys under normal conditions. SGLT1, encoded by the SLC5A1 gene, is primarily expressed in the late proximal tubule (S3 segment) and accounts for the remaining 3% of glucose reabsorption.

In addition to SGLT1 and SGLT2, there are 10 other members in the human protein family SLC5A.

SLC5A4, also known as SGLT3, is a member of the sodium-glucose cotransporter family. Unlike SGLT1 and SGLT2, which are efficient glucose transporters, SGLT3 functions primarily as a glucose sensor rather than a transporter. It has a low affinity for glucose and does not significantly contribute to glucose transport across cell membranes. Instead, SGLT3 acts as a glucose-gated ion channel, generating small depolarizing currents in response to extracellular glucose. This electrical signaling function suggests a role in glucose sensing and signaling pathways rather than in glucose transport.

The SLC5 family includes transporters for a diverse range of substrates beyond glucose. Specific members of this family are specialized for the transport of:

• Mannose (SLC5A9, also known as SGLT4)
• Myo-inositol (SLC5A3, also known as SMIT1)
• Choline (SLC5A7, also known as CHT1)
• Iodide (SLC5A5, also known as NIS)
• Vitamins, specifically biotin and pantothenate (SLC5A6, also known as SMVT)
• Short-chain fatty acids (SLC5A8 and SLC5A12, also known as SMCT1 and SMCT2 respectively)

Each of these transporters plays a specific role in cellular metabolism and homeostasis, often utilizing sodium gradients for substrate transport similar to the glucose transporters in this family.

Mechanism

The transport of glucose across the proximal tubule cell membrane involves a complex process of secondary active transport (also known as co-transport). This process begins with the Na+/K+ ATPase on the basolateral membrane. This enzyme uses ATP to pump 3 sodium ions out of the cell into the blood while bringing 2 potassium ions into the cell. This action creates a sodium concentration gradient across the cell membrane, with a lower concentration inside the cell compared to both the blood and the tubular lumen.

SGLT proteins utilize this sodium gradient to transport glucose across the apical membrane into the cell, even against the glucose concentration gradient. This mechanism is an example of secondary active transport. Once inside the cell, glucose is then moved across the basolateral membrane into the peritubular capillaries by members of the GLUT family of glucose uniporters.

SGLT1 and SGLT2 are classified as symporters because they move sodium and glucose in the same direction across the membrane. To maintain this process, the Sodium–hydrogen antiporter plays a crucial role in replenishing intracellular sodium levels. Consequently, the net effect of glucose transport is coupled with the extrusion of protons from the cell, with sodium serving as an intermediate in this process.

SGLT2 inhibitors for diabetes

Main article: Gliflozin

SGLT2 inhibitors, also called gliflozins, are used in the treatment of type 2 diabetes. SGLT2 is only found in kidney tubules and in conjunction with SGLT1 resorbs glucose into the blood from the forming urine. By inhibiting SGLT2, and not targeting SGLT1, glucose is excreted which in turn lowers blood glucose levels. Examples include dapagliflozin (Farxiga in US, Forxiga in EU), canagliflozin (Invokana) and empagliflozin (Jardiance). Certain SGLT2 inhibitors have shown to reduce mortality in type 2 diabetes. The safety and efficacy of SGLT2 inhibitors have not been established in patients with type 1 diabetes, and FDA has not approved them for use in these patients.

History

In August 1960, in Prague, Robert K. Crane presented for the first time his discovery of the sodium-glucose cotransport as the mechanism for intestinal glucose absorption.

Crane's discovery of cotransport was the first-ever proposal of flux coupling in biology.

References

References

1. (February 2010). "Glucose transporters in the 21st Century". American Journal of Physiology. Endocrinology and Metabolism.
2. (September 2020). "Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences". Current Opinion in Nephrology and Hypertension.
3. [http://www.ensembl.org/Homo_sapiens/familyview?family=ENSF00000000509 Ensembl release 48: Homo sapiens Ensembl protein family ENSF00000000509]
4. (September 2003). "A glucose sensor hiding in a family of transporters". Proceedings of the National Academy of Sciences of the United States of America.
5. (September 2020). "Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application". Pflügers Archiv.
6. (January 2007). "Active sugar transport in health and disease". Journal of Internal Medicine.
7. (January 2001). "Renal Na(+)-glucose cotransporters". American Journal of Physiology. Renal Physiology.
8. (April 2011). "Biology of human sodium glucose transporters". Physiological Reviews.
9. (September 2020). "Glucose transporters in the kidney in health and disease". Pflügers Archiv: European Journal of Physiology.
10. (December 2015). "Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside". Diabetes Care.
11. (September 2022). "The sugar daddy: the role of the renal proximal tubule in glucose homeostasis". American Journal of Physiology. Cell Physiology.
12. (2022). "The Na+/H+ Exchanger 3 in the Intestines and the Proximal Tubule of the Kidney: Localization, Physiological Function, and Key Roles in Angiotensin II-Induced Hypertension". Frontiers in Physiology.
13. (December 2021). "The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?". The Journal of Membrane Biology.
14. "SGLT2 Inhibitors (Gliflozins)". [[Diabetes.co.uk]].
15. (November 2015). "Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes". The New England Journal of Medicine.
16. (2018-12-28). "Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors". U.S. Food and Drug Administration (FDA).
17. (1961). "Membrane Transport and Metabolism. Proceedings of a Symposium held in Prague, August 22–27, 1960". [[Academy of Sciences of the Czech Republic.
18. (February 2004). "The sodium/glucose cotransport family SLC5". Pflügers Archiv.
19. (March 2008). "Facts, fantasies and fun in epithelial physiology". Experimental Physiology.